Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
Junshik Hong, Sun Young Kyung, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jung, Jae-Ik Lee, Se Hoon Park, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
Korean J Intern Med. 2010;25(3):294-300. Published online 2010 Aug 31 DOI: https://doi.org/10.3904/kjim.2010.25.3.294
Citations to this article as recorded by 
Efficacy and Safety of Pemetrexed and Gefitinib in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis
Zhihao Zhang, Xiyong Wang, Huaiqing Xiao, Dongqiang Wu, Dongliang Zhang, Qun Yu, Linna Yuan, Tao Huang
Computational and Mathematical Methods in Medicine.2021; 2021: 1. CrossRef
Pemetrexed versus Gefitinib as Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
Huiyu Wang, Zunjing Zhang, Feng Liu, Miaoying Zhou, Handi Lv
Pteridines.2019; 30(1): 171. CrossRef
Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer
Wenxiong Zhang, Yiping Wei, Dongliang Yu, Jianjun Xu, Jinhua Peng
Medicine.2018; 97(16): e0460. CrossRef
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
Wenxiong Zhang, Yiping Wei, Dongliang Yu, Jianjun Xu, Jinhua Peng
BMC Cancer.2018;[Epub] CrossRef
Gefitinib for advanced non-small cell lung cancer
Esther HA Sim, Ian A Yang, Richard Wood-Baker, Rayleen V Bowman, Kwun M Fong
Cochrane Database of Systematic Reviews.2018;[Epub] CrossRef
Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis
Zuyao Yang, Allan Hackshaw, Qi Feng, Xiaohong Fu, Yuelun Zhang, Chen Mao, Jinling Tang
International Journal of Cancer.2017; 140(12): 2805. CrossRef
Lymphatic invasion is a significant indicator of poor patient prognosis in lung squamous cell carcinoma
Ryota Masuda, Hiroshi Kijima, Madoka Nito, Atsushi Wada, Tomohiko Matsuzaki, Yoichiro Ikoma, Kenei Nakazato, Daisuke Masuda, Makiko Tanaka, Hiroyuki Kobayashi, Sadaki Inokuchi, Masayuki Iwazaki
Molecular Medicine Reports.2017; 15(4): 2067. CrossRef
Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non‑small cell lung cancer: A network meta‑analysis
Yuanyuan Liu, Yu Zhang, Gangling Feng, Qiang Niu, Shangzhi Xu, Yizhong Yan, Shugang Li, Mingxia Jing
Experimental and Therapeutic Medicine.2017;[Epub] CrossRef
Invasion Types Are Associated With Poor Prognosis in Lung Squamous Carcinoma Patients
Yang Zhao, Hongchang Shen, Chen Qiu, Tiehong Zhang, Pingping Hu, Xiao Qu, Qi Liu, Jiajun Du
Medicine.2015; 94(43): e1634. CrossRef
Podoplanin expression is correlated with the prognosis of lung squamous cell carcinoma
Yoichiro IKOMA, Hiroshi KIJIMA, Ryota MASUDA, Makiko TANAKA, Sadaki INOKUCHI, Masayuki IWAZAKI
Biomedical Research.2015; 36(6): 393. CrossRef
Ki-67 labeling index affects tumor infiltration patterns of lung squamous cell carcinoma
DAISUKE MASUDA, RYOTA MASUDA, TOMOHIKO MATSUZAKI, NAOKO IMAMURA, NAOHIRO ARUGA, MAKIKO TANAKA, SADAKI INOKUCHI, HIROSHI KIJIMA, MASAYUKI IWAZAKI
Molecular Medicine Reports.2015; 12(5): 7303. CrossRef
Pemetrexed induces apoptosis in malignant mesothelioma and lung cancer cells through activation of reactive oxygen species and inhibition of sirtuin 1
KI-EUN HWANG, YOUNG-SUK KIM, YU-RI HWANG, SU-JIN KWON, DO-SIM PARK, BYONG-KI CHA, BYOUNG-RYUN KIM, KWON-HA YOON, EUN-TAIK JEONG, HAK-RYUL KIM
Oncology Reports.2015; 33(5): 2411. CrossRef
Use of pemetrexed for non-small cell lung cancer in the Andalusian public health system
María Antonia Pérez-Moreno, Jesús Cotrina-Luque, Mercedes Galván-Banqueri, Sandra Flores-Moreno, Francisco Javier Bautista-Paloma, Miguel Ángel Calleja-Hernández
Journal of Chemotherapy.2015; 27(6): 371. CrossRef
Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction
KI-EUN HWANG, YOUNG-SUK KIM, YU-RI HWANG, SU-JIN KWON, DO-SIM PARK, BYONG-KI CHA, BYOUNG-RYUN KIM, KWON-HA YOON, EUN-TAIK JEONG, HAK-RYUL KIM
International Journal of Oncology.2014; 45(4): 1769. CrossRef
Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study (SELINE)
Kwan-Ho Lee, Kye-Young Lee, Young-June Jeon, Maan-Hong Jung, Choonhee Son, Min-Ki Lee, Jeong-Seon Ryu, Sei-Hoon Yang, Jae-Cheol Lee, Young-Chul Kim, Sun-Young Kim
Tuberculosis and Respiratory Diseases.2012; 73(6): 303. CrossRef
Traitement de rattrapage par pémétrexed pour les CBNPC : étude rétrospective d’implémentation
C. Jungels, T. Berghmans, A.-P. Meert, J.-J. Lafitte, A. Scherpereel, J.-P. Sculier
Revue des Maladies Respiratoires.2012; 29(1): 21. CrossRef
Anti‐tumour activity of 4‐(4‐fluorophenyl)amino‐5,6,7‐trimethoxyquinazoline against tumour cells in vitro
Yinjiu Huang, Fang Liu, Li Zhao, Huazhang Wu, Hui Liu
Cell Biology International.2012; 36(4): 377. CrossRef
Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients
RYOTA MASUDA, HIROSHI KIJIMA, NAOKO IMAMURA, NAOHIRO ARUGA, YUSUKE NAKAMURA, DAISUKE MASUDA, HARUKA TAKEICHI, NOBUSUKE KATO, TOMOKI NAKAGAWA, MAKIKO TANAKA, SADAKI INOKUCHI, MASAYUKI IWAZAKI
Molecular Medicine Reports.2012; 6(5): 937. CrossRef
Endoscopic Cryotherapy of Lung and Bronchial Tumors: A Systematic Review
Seon-Heui Lee, Won-Jung Choi, Sook-Whan Sung, Young-Kyoon Kim, Chi-Hong Kim, Jae-Il Zo, Kwang-Joo Park
The Korean Journal of Internal Medicine.2011; 26(2): 137. CrossRef
Comparison of Therapeutic Efficacy of Gefitinib and Erlotinib in Patients with Squamous Cell Lung Cancer
Hong-Joon Shin, Tae-Ok Kim, Hyun-Wook Kang, Su-Young Chi, Hee-Jung Ban, Soo-Ok Kim, Yong-Soo Kwon, In-Jae Oh, Kyu-Sik Kim, Yu-Il Kim, Sung-Chul Lim, Young-Chul Kim
Tuberculosis and Respiratory Diseases.2011; 71(1): 15. CrossRef
Customizing systemic therapy in patients with advanced non-small cell lung cancer
A. M. Sadowska, V. Nowé, A. Janssens, E. Boeykens, W. A. De Backer, P. R. Germonpré
Therapeutic Advances in Medical Oncology.2011; 3(4): 207. CrossRef